Earnings

NEW YORK , Feb. 17, 2021 - Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow $2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding market Increasing outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%

NEW YORK, NY, January 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, January 8, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share, reflecting a 13% increase in the company’s quarterly dividend over the previous quarter’s dividend.

NEW YORK , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per

NEW YORK , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00

NEW YORK, NY – October 15, 2020 – Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1

NEW YORK , Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020 , to shareholders of record at the close of

NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering.

NEW YORK, NY – September 2, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion